Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 0.78 |
| ▸ | RAB9A | P51151 | 11/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.78 |
| ▸ | MAPT | P10636 | 7/20 | 0.78 |
| ▸ | GAA | P10253 | 3/20 | 0.78 |
| ▸ | HPGD | P15428 | 7/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 5/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2681611 | 0.88 | NPC1 (1.00) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL11284874 | 0.84 | ALDH1A1 (0.71) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL12072142 | 0.83 | NPC1 (0.71) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL17968230 | 0.82 | SMN1; SMN2 (0.67) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL12071677 | 0.82 | ALDH1A1 (0.69) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL9984941 | 0.82 | ALDH1A1 (0.69) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL14129024 | 0.81 | NPC1 (0.61) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL22955874 | 0.81 | ALDH1A1 (0.52) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL29424535 | 0.80 | NPC1 (1.00) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL218892 | 0.80 | NPC1 (1.00) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10022357-B2 | Amyloid precursor protein MRNA blockers for treating Down syndrome and Alzheimer's disease | THE GENERAL HOSPITAL CORPORATION (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| US-20160074367-A1 | AMYLOID PRECURSOR PROTEIN MRNA BLOCKERS FOR TREATING DOWN SYDNROME AND ALZHEIMER'S DISEASE | THE BROAD INSTITUTE, INC. | 2016-03-17 | — | — | US | disclosed |
| WO-2014179303-A1 | AMYLOID PRECURSOR PROTEIN MRNA BLOCKERS FOR TREATING DOWN SYNDROME AND ALZHEIMER'S DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-06 | — | — | WO | disclosed |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-16 | — | — | US | disclosed |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-09 | — | — | US | disclosed |
| US-8518980-B2 | Treatment of Duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-27 | — | — | US | disclosed |
| US-8501713-B2 | Drug combinations for the treatment of duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10022357-B2 | Amyloid precursor protein MRNA blockers for treating Down syndrome and Alzheimer's disease | APP, UPF1, BACE1 | NPC1 1730/4885RAB9A 2552/4885ALDH1A1 3698/4885 |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | NPC1 2477/4885RAB9A 3748/4885ALDH1A1 1203/4885 |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | PYGM, CPT1B, GYS1 | NPC1 2477/4885RAB9A 3748/4885ALDH1A1 1203/4885 |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | NPC1 3637/4885RAB9A 4325/4885ALDH1A1 1652/4885 |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | NPC1 3637/4885RAB9A 4325/4885ALDH1A1 1652/4885 |
| US-20160074367-A1 | AMYLOID PRECURSOR PROTEIN MRNA BLOCKERS FOR TREATING DOWN SYDNROME AND ALZHEIMER'S DISEASE | APP, UPF1, GAP43 | NPC1 1230/4885RAB9A 1925/4885ALDH1A1 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.